Nipocalimab

尼卡利单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameNipocalimab
Drug Alias NameNipocalimab-aahuIMAAVY安力威M-281JNJ-80202135
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonists
TargetsIgG receptor FcRn large subunit p51
Therapy Area/IndicationsHemolysisPemphigoid, BullousLupus Erythematosus, Systemic +[11] 
Global Approved IndicationsMyasthenia Gravis
Approved Indications in ChinaMyasthenia Gravis
Original Approved Country/TerritoryUnited States
Original Approved Date2025/04/29
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMomenta Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen R&D LlcJohnson & Johnson (China) Investment LtdJanssen-Cilag International Nv +[10] 
Inactive CompaniesMomenta Pharmaceuticals Inc
Active IndicationsHemolysisPemphigoid, BullousLupus Erythematosus, Systemic +[10] 
Inactive IndicationsLupus Nephritis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG